| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000005839 |
| Receipt No. | R000006850 |
| Official scientific title of the study | The surveillance study of nausea and vomiting associated with transcatheter arterial chemoembolization for hepatocellular carcinoma |
| Date of disclosure of the study information | 2011/07/01 |
| Last modified on | 2017/08/28 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | The surveillance study of nausea and vomiting associated with transcatheter arterial chemoembolization for hepatocellular carcinoma | |
| Title of the study (Brief title) | The surveillance study of nausea and vomiting associated with transcatheter arterial chemoembolization for hepatocellular carcinoma | |
| Region |
|
|
| Condition | ||
| Condition | Hepatocellular carcinoma | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The purpose of this study is to evaluate symptom including nausea and vomiting induced by transacatheter arterial chemoembolization for hepatocellular carcinoma, change of the level of emetic factor including substance P and serotonin, and antiemetic effects of antagonists for NK1 receptor and 5-HT3 receptor. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The primary outcomes of this study is the incidence of nausea and vomiting without antiemetic drugs and the rate of symptom amelioration by antiemetic drugs after transcatheter arterial chemoembolization for hepatocellular carcinoma. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | control
|
|
| Interventions/Control_2 | NK1 receptor antagonist | |
| Interventions/Control_3 | 5-HT3 receptor antagonist | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | the patients who are diagnosed as hepatocellular carcinoma and candidates for transcatheter arterial chemoembolization | |||
| Key exclusion criteria | (1)Child Pugh score C
(2)hepatic encephalopathy II or more (3)total bilirubin 3.0mg/dL or more (4)the patients who are treated for neuropsychiatric disorder (5)the patients who takes anti-anxiety agent (6)the patients who takes Pimozide (7)the patients who are judged to be ineligible for entry of this study |
|||
| Target sample size | 300 | |||
| Research contact person | |
| Name of lead principal investigator | Takayuki Yakushijin |
| Organization | Osaka University Graduate School of Medicine |
| Division name | Department of Gastroenterology and Hepatology |
| Address | 2-2 Yamadaoka, Suita, Osaka, Japan |
| TEL | 06-6879-3621 |
| yakushijin@gh.med.osaka-u.ac.jp | |
| Public contact | |
| Name of contact person | Takayuki Yakushijin |
| Organization | Osaka University Graduate School of Medicine |
| Division name | Department of Gastroenterology and Hepatology |
| Address | 2-2 Yamadaoka, Suita, Osaka, Japan |
| TEL | 06-6879-3621 |
| Homepage URL | |
| yakushijin@gh.med.osaka-u.ac.jp | |
| Sponsor | |
| Institute | Osaka University Graduate School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Osaka University Graduate School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000006850 |